Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Feb 28;3(1):e000780.
doi: 10.1161/JAHA.113.000780.

Heart failure and breast cancer therapies: moving towards personalized risk assessment

Sanjeev A Francis  1 , Susan Cheng, Carlos L Arteaga, Javid Moslehi
Affiliations
Editorial

Heart failure and breast cancer therapies: moving towards personalized risk assessment

Sanjeev A Francis et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; breast cancer; cardiotoxicity; cardio‐oncology; trastuzumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed integrated cardiac risk assessment for patients undergoing breast cancer treatment.
See this image and copyright information in PMC

Comment in

References

    1. Moslehi J, Cheng S. Cardio‐oncology: it takes two to translate. Sci Transl Med. 2013; 5:187fs20 - PubMed
    1. Slamon DJ, Leyland‐Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-792 - PubMed
    1. Burstein HJ, Piccart‐Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab‐based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012; 30:2179-2182 - PMC - PubMed
    1. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M‐C, Sauter G, Minckwitz von G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah‐Fisch I, Lindsay M‐A, Riva A, Crown JBreast Cancer International Research Group Adjuvant trastuzumab in HER2‐positive breast cancer. N Engl J Med. 2011; 365:1273-1283 - PMC - PubMed
    1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan‐Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. N Engl J Med. 2005; 353:1673-1684 - PubMed

Publication types

LinkOut - more resources